文章：

UBE2T在多发性骨髓瘤中的高表达预示着不良的预后和生存

High expression of UBE2T predicts poor prognosis and survival in multiple myeloma 

原文发布日期：2019-01-09 

英文摘要：

Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-related substrates, contributing to DNA repair in the Fanconi anemia pathway. Also, numerous evidences reported that UBE2T is closely related to cell proliferation and carcinogenesis. However, the relationship between MM and UBE2T has not been studied. Here, we integrated eight datasets and analyzed the relationship of expression of UBE2T and ISS, 1q21, relapse and survival in MM 2684 patients (totally 2893 samples). We found that the expression of UBE2T increased with the deterioration of MM (P = 1.4e-07), especially in the early stage. UBE2T is closely related to IgG serotype MM (P = 6.9e-05). High expression of UBE2T is associated with poor survival and prognosis (EFS: P = 1.43e-03, OS: P = 5.47e-05). UBE2T is likely to play a part in the cell division pathway, affecting the survival and prognosis of MM. Therefore, UBE2T could be considered as an early alternative biomarker for the prognosis of MM. 

摘要翻译： 

多发性骨髓瘤（MM）是一种血液系统恶性肿瘤，以浆细胞恶性增殖为主要特征。生物标志物在评估MM进展和预后中具有重要作用。泛素结合酶E2T（UBE2T）通过连接特定E3泛素连接酶降解相关底物，参与范可尼贫血通路中的DNA修复过程。多项研究证据表明UBE2T与细胞增殖和癌变密切相关，但其与MM的关联尚未明确。本研究整合八个数据集，通过对2684例MM患者（共2893个样本）进行分析，探讨了UBE2T表达与国际分期系统（ISS）、1q21扩增、复发及生存期的关联。结果显示：UBE2T表达随MM病情恶化而显著升高（P=1.4e-07），尤其在疾病早期阶段；该基因与IgG血清型MM密切相关（P=6.9e-05）；UBE2T高表达与不良无事件生存期（EFS: P=1.43e-03）和总生存期（OS: P=5.47e-05）显著相关。机制上UBE2T可能通过参与细胞分裂通路影响MM患者的生存预后。因此，UBE2T有望成为MM预后的早期替代生物标志物。

原文链接：

High expression of UBE2T predicts poor prognosis and survival in multiple myeloma